Kamada (KMDA) Change in Account Payables (2012 - 2026)
Kamada's (KMDA) quarterly Change in Account Payables came in at $5.4 million in Q2 2026, up 1498.96% on a YoY basis from $335093.7 in Q2 2025, and up 470.54% quarter-over-quarter from -$1.4 million in Q1 2026.
Analysis
Kamada (KMDA) Change in Account Payables (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Change in Account Payables for 15 consecutive years, with $5.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Change in Account Payables rose 1498.96% year-over-year to $5.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.2 million (down 46.36% YoY), and the FY2025 full-year result was -$6.9 million, down 660.36% from the prior year.
- Change in Account Payables improved to $5.4 million in Q2 2026 per KMDA's latest filing, from -$1.4 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $13.7 million in Q3 2022 and bottomed at -$13.6 million in Q1 2022.
- Historically, Change in Account Payables has averaged -$103444.4 across 5 years, with a median of $125500.0 in 2025.
- The sharpest annual moves came in 2022 and 2026: Change in Account Payables sank 819.74% in 2022, then jumped 1498.96% in 2026.
- Over 5 years, Change in Account Payables stood at $1.2 million in 2022, then jumped by 885.52% to $11.4 million in 2023, then gained by 4.73% to $12.0 million in 2024, then sank by 128.17% to -$3.4 million in 2025, then surged by 258.85% to $5.4 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $5.4 million, -$1.4 million, and -$3.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | -70.00 Mn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 18.00 Mn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | -66.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -8.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 7.11 Mn |
| 10 | Kamada | 473.57 Mn | 403.43 Mn | 22.47 Mn | 5.36 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.36 Mn |
| Mar 31, 2026 | -1.45 Mn |
| Dec 31, 2025 | -3.37 Mn |
| Sep 30, 2025 | 634,000.00 |
| Jun 30, 2025 | -383,000.00 |
| Mar 31, 2025 | -3.75 Mn |
| Dec 31, 2024 | 11.97 Mn |
| Sep 30, 2024 | -5.66 Mn |
| Jun 30, 2024 | 3.69 Mn |
| Mar 31, 2024 | -8.79 Mn |
| Dec 31, 2023 | 11.43 Mn |
| Sep 30, 2023 | -13.18 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | -6.71 Mn |
| Dec 31, 2022 | 1.16 Mn |
| Sep 30, 2022 | 13.74 Mn |
| Jun 30, 2022 | 5.81 Mn |
| Mar 31, 2022 | -13.65 Mn |
| Dec 31, 2021 | 5.19 Mn |
| Sep 30, 2021 | 1.59 Mn |